A Phase 3 interventional study of Magnesium Sulfate 2 G and Magnesium Sulfate 4 G in Tachycardia Atrial, Atrial Fibrillation and Atrial Flutter With Rapid Ventricular Response, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 306th largest by planned enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 100 in phase 3, reaches primary completion later than 67 of the 219 other live ones, and was the 881st registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
Oslo University Hospital · Sites in United States, Belgium, France and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 54 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 153 is close to the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 200 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Wake Forest University Health Sciences has 7 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
76 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 76 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl)
Drug: Magnesium Sulfate 2 G
Magnesium Sulfate 4g/50ml 0.9% NaCl
Drug: Magnesium Sulfate 4 G
50ml 0.9% NaCl
Drug: Saline
Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Also known as: Magnesium Sulfate 2 gram/50ml 0.9% NaCl
Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Also known as: Magnesium Sulfate 4g/50ml 0.9% NaCl
The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Also known as: Control (50ml 0.9% NaCl)
Ventricular rate control
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 bpm.
Time frame: Within the first 2 hours of intravenous magnesium administration
Time to achieve goal HR (heart rate)
Mean change in heart rate and rhythm after the administration of magnesium sulfate as well as after the administration of diltiazem
Time frame: 2 hours
Rate of conversion
Rate of conversion to normal sinus rhythm (NSR)
Time frame: 2 hours after administration of magnesium
Incidence of hypotension
SBP \< 90 mmHg or MAP (mean arterial pressure) \< 65
Time frame: At 1 and 2 hours after magnesium administration
Change in heart rate
Mean change in heart rate up to 24 hours after magnesium infusion
Time frame: up to 24 hours after magnesium infusion
Clinical need for rescue medication administration
Dose and route of rescue medications given (magnesium and diltiazem)
Time frame: 2 hours from diltiazem administration
Adverse effects
Patient reported adverse effects (e.g.. flushing, headache, nausea, new onset or worsening lightheadedness since beginning the magnesium infusion)
Time frame: 2 hours from diltiazem administration
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 26 months is below that.
Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magnesium Sulfate
Wake Forest University Health Sciences →